Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

MiRXES

Explore full profile

Biotechnology, Cancer Diagnostics, Health Care, Life Science

Singapore, SingaporeFounded 2014Biotech & Life Sciences
Valuation $1.57B Market cap · 2025
Revenue $50–100M Latest reported FY

About MiRXES

MiRXES is a biotechnology startup that operates in the healthcare sector, specifically focusing on the diagnosis and treatment of cancer and other diseases. The company's primary mission is to leverage scientific advancements to combat cancer, a disease that affects one in four people globally.

MiRXES operates in the medical diagnostics market, providing innovative solutions that range from discovery tools and services to diagnostic tests. These tests are designed to detect a variety of conditions, including cancer, cardiovascular diseases, metabolic disorders, and infectious diseases. The company's solutions are designed to enable early action, which is critical in managing these conditions effectively.

The company's business model revolves around the development and commercialization of these diagnostic tests. They generate revenue by selling these tests to healthcare providers and institutions. In addition, they also offer precision oncology services, which involve tailoring cancer treatment plans based on the individual genetic makeup of the patient's tumor. This personalized approach to cancer treatment is becoming increasingly popular and could represent a significant growth opportunity for the company.

MiRXES serves a diverse range of clients, including hospitals, clinics, and other healthcare providers. The company's solutions are designed to be used in a clinical setting, helping healthcare professionals to diagnose diseases early and accurately, thereby improving patient outcomes.

In summary, MiRXES is a biotech startup that uses science to fight cancer and other diseases. They develop and sell diagnostic tests and offer precision oncology services to healthcare providers, aiming to enable early action and improve patient outcomes.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2014
Headquarters
Singapore, Singapore
Listing
IPO 2025
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • VentureCraft

Series A1 investor entered at this stage

  • MiRXES Innovation

Series B and later13 investors entered at this stage

  • CR-CP Life Science Fund
  • Rock Springs Capital
  • CCBI Tech Venture
  • EDBI
  • Keytone Ventures
  • Charoen Pokphand
  • CCB International
  • CDG Invest Growth
  • New Horizons Venture Capital
  • Mitsui Global Investment
  • Beijing Fellow Partners
  • NHH Ventures
  • CBC Group
Employees mapped 153 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇸🇬 Singapore85.6%
🇺🇸 United States5.1%
🇯🇵 Japan3.4%
🇨🇳 China2.5%
🇭🇰 Hong Kong2.5%
Top 5 of 6 shown
Web traffic by country
7.7K monthly visits
across markets
🇸🇬 Singapore24.7%
🇦🇺 Australia22.1%
🇺🇸 United States20.8%
🇮🇳 India15.6%
🇲🇾 Malaysia10.4%
Top 5 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about MiRXES on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MiRXES on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.